BiotechTube

Camrelizumab + Cisplatin or Carboplatin

Phase 2UNKNOWN
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cervical Cancer

Conditions

Cervical Cancer

Trial Timeline

May 20, 2021 → May 20, 2023

NCT ID
NCT04974827

About Camrelizumab + Cisplatin or Carboplatin

Camrelizumab + Cisplatin or Carboplatin is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Cervical Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT04974827. Target conditions include Cervical Cancer.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT05151549Phase 2UNKNOWN
NCT04974827Phase 2UNKNOWN

Competing Products

20 competing products in Cervical Cancer

See all competitors
ProductCompanyStageHype Score
PRGN-2009 plus Pembrolizumab + Pembrolizumab alonePrecigenPhase 2
47
ABP-450AEON BiopharmaPhase 2
44
ABP-450 + PlaceboAEON BiopharmaPhase 2
44
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
exatecan mesylateDaiichi SankyoPhase 2
52
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Sacituzumab tirumotecan plus IparomlimabSun PharmaceuticalPhase 2
52
Amolimogene + AmolimogeneEisaiPhase 2/3
65
BOTULINUM TOXIN TYPE BEisaiPhase 2
52
Gemzar (gemcitabine)Eli LillyPhase 3
77
PemetrexedEli LillyPhase 2
52
SHR-A1811 InjectionJiangsu Hengrui MedicinePhase 2
52
camrelizumab； famitinib malate + platinum-based chemotherapyJiangsu Hengrui MedicinePhase 3
77
SHR-1210 + SHR-1020 + Physician's choice chemotherapyJiangsu Hengrui MedicinePhase 2
52
Camrelizumab + Cisplatin or CarboplatinJiangsu Hengrui MedicinePhase 2
52
Volrustomig + Cisplatin + Carboplatin + PaclitaxelAstraZenecaPhase 2
52
VolrustomigAstraZenecaPhase 3
77
Durvalumab + Cisplatin + CarboplatinAstraZenecaPhase 3
77
VolrustomigAstraZenecaPhase 2
52
PembrolizumabMerckPhase 2
52

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85